Rein Therapeutics, Inc.

The company is a clinical-stage biopharmaceutical business that develops novel therapeutics targeting orphan pulmonary and fibrosis indications with limited or no approved therapies. Its primary pipeline candidate is LTI-03, an inhaled peptide therapeutic derived from the Cav1 protein designed to protect lung epithelial cells and inhibit pro-fibrotic pathways in idiopathic pulmonary fibrosis. The company also developed LTI-01, a proenzyme for treating loculated pleural effusion, alongside preclinical programs for cystic fibrosis and systemic fibrosis, although active development on these secondary programs is paused. Because its drug candidates remain in clinical and preclinical development, the company has no commercialized products, generates no product sales revenue, and currently lacks commercial customers or internal sales, marketing, and distribution infrastructure.

The company operates without internal manufacturing facilities, relying entirely on third-party contract manufacturers for drug supplies. Its clinical development activities span multiple countries, including clinical trial sites located across the United States, the United Kingdom, Germany, Poland, Belgium, Australia, and New Zealand. The provided text does not state the company's headquarters location.

Summary of the business section of Rein Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 10 full-time employees, including a total of two employees with M.D.”